CT-P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, Active-Controlled, Phase 3 Study.

Background: This study compared the therapeutic equivalence of CT-P39 (an omalizumab biosimilar) and EU-approved reference omalizumab (ref-OMA) in patients with chronic spontaneous urticaria.

Methods: This double-blind, randomized, active-controlled Phase 3 study (NCT04426890) included two 12-week treatment periods (TPs). In TP1, patients received CT-P39 300 mg, ref-OMA 300 mg, CT-P39 150 mg, or ref-OMA 150 mg.

INDICATORS OF THE CELL-MEDIATED IMMUNITY IN SURGICAL PATIENTS WITH GASTRODUODENAL ULCERS COMPLICATED BY BLEEDING.

Objective: The aim: To determine the peculiarities of indicators dynamic of cellular level of immunity in patients with gastroduodenal ulcer complicated by bleeding and microbial contamination the periulcerous area.

Patients And Methods: Materials and methods: 80 patients with gastroduodenal ulcers complicated by bleeding were studied. Among patients in the main group, 18 (22.